Liver Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics,

Liver Cancer Pipeline constitutes 70+ key companies continuously working towards developing 75+ Liver Cancer treatment therapies, analyzes DelveInsight.

Liver Cancer Overview:

Cancer occurs when cells in the body grow uncontrollably. When this abnormal growth begins in the liver, it is known as liver cancer. In the United States, approximately 25,000 men and 11,000 women are diagnosed with liver cancer each year, with around 19,000 men and 9,000 women dying from the disease. While liver cancer rates increased for several decades, they are now declining. However, the condition remains more prevalent in other regions of the world compared to the U.S.

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, ranks as the fifth most common cancer in men and the seventh most common in women. It is also the third leading cause of cancer-related deaths worldwide. HCC, which originates from hepatocytes, accounts for over 80% of liver cancer cases. It is often linked to liver cirrhosis caused by chronic liver conditions such as hepatitis B (HBV), hepatitis C (HCV), and autoimmune hepatitis. Additional risk factors include excessive alcohol consumption, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), aflatoxin exposure, diabetes, smoking, and genetic disorders like alpha-1 antitrypsin deficiency, hemochromatosis, tyrosinemia, porphyria, and Wilson's disease.

Common symptoms of liver cancer include fatigue, abdominal pain, swelling due to fluid buildup (ascites), pain in the right shoulder, loss of appetite, nausea, unintended weight loss, jaundice (yellowing of the skin and eyes), pale-colored stools, and fever. These symptoms typically become more noticeable as the cancer progresses.

Request for a detailed insights report on Liver Cancer pipeline insights @ https://www.delveinsight.com/report-store/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Liver Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Liver Cancer Therapeutics Market.

Key Takeaways from the Liver Cancer Pipeline Report

DelveInsight's Liver Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Liver Cancer treatment.
In December 2024, Galectin Therapeutics reported results from its global NAVIGATE clinical trial, which assessed belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.
In October 2024, PharmaIN Corporation revealed that it would present interim findings from its ongoing Phase I clinical trial of PHIN-214, its lead candidate, for preventing and treating decompensated cirrhosis.
In June 2024, Carisma Therapeutics Inc. announced the selection of its first development candidate from its collaboration with Moderna, Inc. The candidate is an in vivo CAR-M targeting Glypican-3, designed to treat solid tumors such as hepatocellular carcinoma. This milestone triggered a $2 million payment to Carisma.
In June 2024, Resolution Therapeutics Limited shared important data on RTX001 in collaboration with the University of Edinburgh at the EASL Congress 2024 in Milan, Italy, highlighting the potential of macrophage cell therapy for treating advanced liver cirrhosis.
In June 2024, Lipocine presented Phase II results for LPCN 1148 in cirrhosis at the European Association for the Study of Liver (EASL) Congress in Milan, Italy, through a late-breaking oral presentation.
In May 2024, Ascelia Pharma AB reported that its liver imaging drug candidate, Orviglance, significantly improved the visualization of focal liver lesions, successfully meeting the primary endpoint in the pivotal Phase III SPARKLE study.
In April 2024, LyGenesis announced the first patient had been treated in its Phase IIa clinical trial of its first-in-class allogenic regenerative cell therapy, which is transplanted into patients' lymph nodes as a potential treatment for end-stage liver disease (ESLD).
In March 2024, Lipocine announced positive topline results from its Phase II study of LPCN 1148, an oral candidate being developed for the clinical management of liver cirrhosis.
In February 2024, Immune-Onc Therapeutics, Inc. revealed a Phase Ib/II clinical trial collaboration with Roche to evaluate Immune-Onc's IO-108, a first-in-class antibody targeting LILRB2 (ILT4), in combination with Roche's atezolizumab and bevacizumab for treating patients with locally advanced, metastatic, and/or unresectable hepatocellular carcinoma (HCC).
In February 2024, Biosyngen announced that BST02 received Fast Track Designation from the U.S. FDA for the treatment of all liver cancer types, including hepatocellular carcinoma and cholangiocarcinoma.
In January 2024, CARsgen Therapeutics Holdings Limited announced that CT011 received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) for patients with GPC3-positive stage IIIa hepatocellular carcinoma at high risk of recurrence after surgical resection.
Key Liver Cancer companies such as Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, Bristol-Myers Squibb, and others are evaluating new drugs for Liver Cancer to improve the treatment landscape.
Promising Liver Cancer pipeline therapies in various stages of development include Namodenoson, YIV-906, TTI-101, STP707, BST02, and others.

Liver Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Liver Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liver Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Liver Cancer market.

Download our free sample page report on Liver Cancer pipeline insights @ https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Liver Cancer Emerging Drugs

Namodenoson: Can-Fite BioPharma
YIV-906: Yiviva
TTI-101: Tvardi Therapeutics
STP707: Sirnaomics
BST02: BioSyngen

Liver Cancer Companies

Around 70 or more major companies are actively developing therapies for liver cancer. Among them, Can-Fite BioPharma has a drug candidate in the most advanced stage of development, specifically Phase III.

DelveInsight's report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Liver Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Liver Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Liver Cancer Therapies and Key Companies: Liver Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Liver Cancer Pipeline Therapeutic Assessment
• Liver Cancer Assessment by Product Type
• Liver Cancer By Stage
• Liver Cancer Assessment by Route of Administration
• Liver Cancer Assessment by Molecule Type

Download Liver Cancer Sample report to know in detail about the Liver Cancer treatment market @ Liver Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Liver Cancer Current Treatment Patterns
4. Liver Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Liver Cancer Late-Stage Products (Phase-III)
7. Liver Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Liver Cancer Discontinued Products
13. Liver Cancer Product Profiles
14. Liver Cancer Key Companies
15. Liver Cancer Key Products
16. Dormant and Discontinued Products
17. Liver Cancer Unmet Needs
18. Liver Cancer Future Perspectives
19. Liver Cancer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Liver Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.